Most Read Articles
Elvira Manzano, 4 days ago
Bisphosphonates have proven antifracture efficacy and remain to be the cornerstone of osteoporosis treatment. However, a drug holiday is of particular importance with bisphosphonates due to some signals with long-term use of the drug, including rare incidence of atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ), says a leading endocrinologist at AFOS 2017.
Yesterday
Breast cancer patients have notably different microbiomes in the local breast tissue and urinary tract, a recent study reveals. Particularly, species in the Methylobacterium genus are reduced in the local breast tissue while the urinary tract is enriched in gram-positive bacteria.
Pearl Toh, 13 Oct 2017
Women with higher plasma tryptophan concentrations were less likely to have poor sleep quality during pregnancy, especially among those with anxiety symptoms, according to the GUSTO* study.
Tristan Manalac, Yesterday
Statin use, particularly in smokers, obese patients and nondiabetics, has a strong and dose-dependent association with decreasing risk of pancreatic ductal adenocarcinoma (PDAC), according to a new study.

Secukinumab delivers better QoL improvement in psoriasis than etanercept

06 Apr 2017

Quality-of-life (QoL) improvements in patients with psoriasis are faster and greater with secukinumab than etanercept treatment, according to a recent study.

The analysis centred on the effect of secukinumab treatment on patient-reported health-related QoL as evaluated by the Dermatology Life Quality Index (DLQI) in patients with moderate to severe psoriasis. Researchers compared between secukinumab and etanercept the proportion of participants (n=1,470) achieving DLQI score 0/1 response at week 24, time to DLQI score 0/1 response and sustained DLQI score 0/1 response up to week 52.

Of the participants, 1,144 received secukinumab and 326 etanercept. Patients in the secukinumab group had significantly higher DLQI score 0/1 response rates than those in the etanercept group at week 24. A significantly shorter median time to DLQI score 0/1 response was seen in secukinumab vs etanercept (12 vs 24 weeks; p<0.01).

The DLQI score 0/1 response was achieved by majority of secukinumab-treated patients at week 24. This was sustained through week 52, along with a 90- to 100-percent decrease in the Psoriasis Area and Severity Index total score response.

The study was limited by the insufficient placebo comparisons during the maintenance period due to rerandomization at week 12, according to researchers.

Findings from a prior research showed that patients receiving secukinumab have greater improvements and more effective relief from psoriasis impact on daily activities and personal relationships than those receiving etanercept. [J Dermatolog Treat 2016;21:1-6]

“Psoriasis is a chronic condition with negative impact on patients' quality of life that most often requires lifelong effective and safe treatment,” researchers said.

Editor's Recommendations
Most Read Articles
Elvira Manzano, 4 days ago
Bisphosphonates have proven antifracture efficacy and remain to be the cornerstone of osteoporosis treatment. However, a drug holiday is of particular importance with bisphosphonates due to some signals with long-term use of the drug, including rare incidence of atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ), says a leading endocrinologist at AFOS 2017.
Yesterday
Breast cancer patients have notably different microbiomes in the local breast tissue and urinary tract, a recent study reveals. Particularly, species in the Methylobacterium genus are reduced in the local breast tissue while the urinary tract is enriched in gram-positive bacteria.
Pearl Toh, 13 Oct 2017
Women with higher plasma tryptophan concentrations were less likely to have poor sleep quality during pregnancy, especially among those with anxiety symptoms, according to the GUSTO* study.
Tristan Manalac, Yesterday
Statin use, particularly in smokers, obese patients and nondiabetics, has a strong and dose-dependent association with decreasing risk of pancreatic ductal adenocarcinoma (PDAC), according to a new study.